387 related articles for article (PubMed ID: 28694246)
1. MANAGEMENT OF ENDOCRINE DISEASE: Polycystic ovary syndrome and nonalcoholic fatty liver disease.
Macut D; Božić-Antić I; Bjekić-Macut J; Tziomalos K
Eur J Endocrinol; 2017 Sep; 177(3):R145-R158. PubMed ID: 28694246
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic Fatty Liver Disease in Patients with Polycystic Ovary Syndrome.
Macut D; Bjekić-Macut J; Livadas S; Stanojlović O; Hrnčić D; Rašić-Marković A; Milutinović DV; Mladenović V; Andrić Z
Curr Pharm Des; 2018; 24(38):4593-4597. PubMed ID: 30652641
[TBL] [Abstract][Full Text] [Related]
3. Nonalcoholic fatty liver disease and polycystic ovary syndrome.
Vassilatou E
World J Gastroenterol; 2014 Jul; 20(26):8351-63. PubMed ID: 25024594
[TBL] [Abstract][Full Text] [Related]
4. Hepatic manifestations of women with polycystic ovary syndrome.
Chen MJ; Ho HN
Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome.
Macut D; Tziomalos K; Božić-Antić I; Bjekić-Macut J; Katsikis I; Papadakis E; Andrić Z; Panidis D
Hum Reprod; 2016 Jun; 31(6):1347-53. PubMed ID: 27076501
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Paschou SA; Polyzos SA; Anagnostis P; Goulis DG; Kanaka-Gantenbein C; Lambrinoudaki I; Georgopoulos NA; Vryonidou A
Endocrine; 2020 Jan; 67(1):1-8. PubMed ID: 31538291
[TBL] [Abstract][Full Text] [Related]
7. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial.
Frøssing S; Nylander M; Chabanova E; Frystyk J; Holst JJ; Kistorp C; Skouby SO; Faber J
Diabetes Obes Metab; 2018 Jan; 20(1):215-218. PubMed ID: 28681988
[TBL] [Abstract][Full Text] [Related]
8. Glucagon-like peptide-1 analogue, liraglutide, improves liver fibrosis markers in obese women with polycystic ovary syndrome and nonalcoholic fatty liver disease.
Kahal H; Abouda G; Rigby AS; Coady AM; Kilpatrick ES; Atkin SL
Clin Endocrinol (Oxf); 2014 Oct; 81(4):523-8. PubMed ID: 24256515
[TBL] [Abstract][Full Text] [Related]
9. Understanding the association of polycystic ovary syndrome and non-alcoholic fatty liver disease.
Salva-Pastor N; Chávez-Tapia NC; Uribe M; Nuño-Lámbarri N
J Steroid Biochem Mol Biol; 2019 Nov; 194():105445. PubMed ID: 31381969
[TBL] [Abstract][Full Text] [Related]
10. Prevalence, etiology and management of non-alcoholic fatty liver disease in patients with polycystic ovary syndrome.
Makri E; Tziomalos K
Minerva Endocrinol; 2017 Jun; 42(2):122-131. PubMed ID: 27792214
[TBL] [Abstract][Full Text] [Related]
11. Adverse metabolic phenotype of adolescent girls with non-alcoholic fatty liver disease plus polycystic ovary syndrome compared with other girls and boys.
Ayonrinde OT; Adams LA; Doherty DA; Mori TA; Beilin LJ; Oddy WH; Hickey M; Sloboda DM; Olynyk JK; Hart R
J Gastroenterol Hepatol; 2016 May; 31(5):980-7. PubMed ID: 26589977
[TBL] [Abstract][Full Text] [Related]
12. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome.
Falzarano C; Lofton T; Osei-Ntansah A; Oliver T; Southward T; Stewart S; Andrisse S
J Clin Endocrinol Metab; 2022 Jan; 107(1):258-272. PubMed ID: 34491336
[TBL] [Abstract][Full Text] [Related]
13. Polycystic ovary syndrome with hyperandrogenism as a risk factor for non-obese non-alcoholic fatty liver disease.
Kim JJ; Kim D; Yim JY; Kang JH; Han KH; Kim SM; Hwang KR; Ku SY; Suh CS; Kim SH; Choi YM
Aliment Pharmacol Ther; 2017 Jun; 45(11):1403-1412. PubMed ID: 28370150
[TBL] [Abstract][Full Text] [Related]
14. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis?
Targher G; Rossini M; Lonardo A
Endocrine; 2016 Feb; 51(2):211-21. PubMed ID: 26024975
[TBL] [Abstract][Full Text] [Related]
15. Increased prevalence of polycystic ovary syndrome in premenopausal women with nonalcoholic fatty liver disease.
Vassilatou E; Vassiliadi DA; Salambasis K; Lazaridou H; Koutsomitopoulos N; Kelekis N; Kassanos D; Hadjidakis D; Dimitriadis G
Eur J Endocrinol; 2015 Dec; 173(6):739-47. PubMed ID: 26340970
[TBL] [Abstract][Full Text] [Related]
16. Metabolic consequences of obesity and insulin resistance in polycystic ovary syndrome: diagnostic and methodological challenges.
Jeanes YM; Reeves S
Nutr Res Rev; 2017 Jun; 30(1):97-105. PubMed ID: 28222828
[TBL] [Abstract][Full Text] [Related]
17. Review of nonalcoholic fatty liver disease in women with polycystic ovary syndrome.
Kelley CE; Brown AJ; Diehl AM; Setji TL
World J Gastroenterol; 2014 Oct; 20(39):14172-84. PubMed ID: 25339805
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease in polycystic ovarian syndrome in Indian women.
Siwatch S; Singh V; Dhaliwal LK; Kumari S; Singh K
J Obstet Gynaecol; 2022 Jul; 42(5):957-961. PubMed ID: 34689689
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of non-alcoholic fatty liver disease in women with polycystic ovary syndrome and its correlation with metabolic syndrome.
Romanowski MD; Parolin MB; Freitas AC; Piazza MJ; Basso J; Urbanetz AA
Arq Gastroenterol; 2015; 52(2):117-23. PubMed ID: 26039829
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and predictors of nonalcoholic fatty liver disease in South Asian women with polycystic ovary syndrome.
Shengir M; Krishnamurthy S; Ghali P; Deschenes M; Wong P; Chen T; Sebastiani G
World J Gastroenterol; 2020 Nov; 26(44):7046-7060. PubMed ID: 33311949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
